This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

38/100

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Disease mechanisms

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer's disease (AD) is the leading cause of dementia worldwide and represents a growing public health challenge in aging societies. Despite extensive research efforts, currently approved therapies provide only limited symptomatic benefit and do not halt disease progression. A major obstacle to effective treatment is the blood-brain barrier (BBB), which severely restricts the brain delivery of most therapeutic agents. Nanoparticle-based drug delivery systems have emerged as a promising strategy to overcome BBB-related limitations by enabling precise control over physicochemical properties such as size, surface characteristics, and material composition. These properties can improve drug solubility, stability, pharmacokinetics, and targeted brain accumulation while reducing systemic toxicity. However, efficient BBB penetration and clinically feasible translation remain major challenges. This review summarizes key design principles for nanoparticles intended for AD therapy and highlights representative platforms with translational considerations, particularly lipid-based and polymer-based nanoparticles. In addition, alternative delivery strategies-including nose-to-brain nanoparticle systems and nanoparticles exploiting receptor-mediated and adsorptive-mediated transcytosis, as well as synaptic dysfunction targeting-are discussed. Collectively, this review outlines current advances and future directions for nanoparticle-mediated therapeutic delivery in AD.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Roamcharern, N., & Yubolphan, R. (2026). Overcoming the blood–brain barrier in Alzheimer's disease: translational perspectives on advanced drug delivery platforms. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2026.1810486

Vancouver

Roamcharern N, Yubolphan R. Overcoming the blood–brain barrier in Alzheimer's disease: translational perspectives on advanced drug delivery platforms. Frontiers in Neuroscience. 2026. doi:10.3389/fnins.2026.1810486. PMID: 42222363.

BibTeX

@article{roamcharern2026-42222363,
  author  = {Roamcharern, Napaporn and Yubolphan, Ruedeemars},
  title   = {{Overcoming the blood–brain barrier in Alzheimer's disease: translational perspectives on advanced drug delivery platforms}},
  journal = {Frontiers in Neuroscience},
  year    = {2026},
  doi     = {10.3389/fnins.2026.1810486},
  pmid    = {42222363},
  url     = {https://doi.org/10.3389/fnins.2026.1810486}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

These properties can improve drug solubility, stability, pharmacokinetics, and targeted brain accumulation while reducing systemic toxicity.
However, efficient BBB penetration and clinically feasible translation remain major challenges.
This review summarizes key design principles for nanoparticles intended for AD therapy and highlights representative platforms with translational considerations, particularly lipid-based and polymer-based nanoparticles.
In addition, alternative delivery strategies-including nose-to-brain nanoparticle systems and nanoparticles exploiting receptor-mediated and adsorptive-mediated transcytosis, as well as synaptic dysfunction targeting-are discussed.
Collectively, this review outlines current advances and future directions for nanoparticle-mediated therapeutic delivery in AD.

Why it matters

This review describes nanoparticle-based drug delivery systems designed to carry Alzheimer's therapies across the blood-brain barrier, which currently blocks most treatments from reaching the brain. It notes that efficient brain penetration and clinical translation remain major challenges, so no treatment is yet proven.

Study details

Evidence strengthLow

How this study scored 38/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Frontiers in Neuroscience)
Journal's citation record	2 / 4	Frontiers in Neuroscience: journal h-index 226 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 4 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.0 citations a year over 2 year(s) since 2026
Impact for its field and year	3 / 6	Cited 5.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 1 other studies in this library
Still being cited	1 / 4	Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	1 / 4	Last-listed author Ruedeemars Yubolphan: h-index 6 (OpenAlex, whole career)
Institution's track record	0 / 3	University of Strathclyde: institution h-index 555 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 2 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 42222363)
Free to read	2 / 2	Free to read
Total	38 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

In the news

1 news article on alzhub's news page cites this paper.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Disease mechanisms from nearby years

Also in Disease mechanisms

128 studies in the library are filed under Disease mechanisms with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Disease mechanisms hub.

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →